

## Nemus THC Pro-Drug Receives Patent in Japan

COSTA MESA, CA -- (Marketwired) -- 10/22/15 -- Nemus Bioscience, Inc.(OTCQB: NMUS) has announced that the pro-drug of tetrahydrocannabinol (THC) in-licensed from the company's research and commercial partner, the University of Mississippi, has been granted a utility patent in Japan. The patent refers to the composition of matter and preparation of delta-9 THC amino acid esters and their methods of use. The lead Nemus compound in development for glaucoma, NB1111, would fall under this patent umbrella.

"Nemus is delighted that this intellectual property has been recognized in Japan," commented Brian Murphy, M.D., M.P.H., who serves as both CEO and Chief Medical Officer of Nemus. "The Japanese therapeutics market is recognized as the world's second largest, behind that of the United States. Pharmaceutical sales from 2013 have been estimated at USD \$113 billion and the management at Nemus recognizes the importance of this market in terms of urgent medical need by an aging population at risk for chronic and progressive eye disease."

"It is very gratifying to have the work of our research team at Ole Miss protected not only in the United States, but internationally as well," stated Dr. Mahmoud ElSohly, professor at the National Center for Natural Products Research at the University. "Blindness arising from a debilitating disease like glaucoma needs to be addressed as the number of patients at-risk continues to increase around the world."

"We are pleased to be collaborating with Nemus as we work to leverage the benefits of a new class of cannabinoid-based therapies for the alleviation of disease burden on a global scale," said Dr. Soumyajit Majumdar, Associate Professor of Pharmaceutics and Drug Delivery and Associate Dean for Research in the School of Pharmacy at the university. "The potential neuroprotective qualities of cannabinoid molecules could hold extra benefit for the majority of Japanese glaucoma patients who suffer optic nerve damage while not experiencing elevated intraocular pressure."

"Nemus looks to further cannabinoid-based drug development in a planned ophthalmologic therapeutic franchise, in addition to developing parallel track compounds for systemic drug exposure for diseases outside of the eye," reported Dr. Murphy. "The pleiotropic quality of cannabinoids makes them ideal for addressing ailments in multiple organ systems and the use of proprietary pro-drugs allows Nemus to develop molecules with better targeted bioavailability and pharmacokinetics."

### ***ABOUT NEMUS BIOSCIENCE, INC.***

The Company is a biopharmaceutical company, headquartered in Costa Mesa, California, focused on the discovery, development, and commercialization of cannabis-based therapeutics for significant unmet medical needs in global markets. Utilizing certain proprietary technology licensed from the University of Mississippi, NEMUS is working to develop novel ways to deliver cannabis-based drugs for specific indications, with the aim of

optimizing the clinical effects of such drugs, while limiting the potential adverse events. NEMUS's strategy will explore the use of natural and synthetic compounds, alone or in combination. The Company is led by a highly qualified team of executives with decades of biopharmaceutical experience and significant background in early-stage drug development. For more information, visit [www.nemusbioscience.com](http://www.nemusbioscience.com).

### **FORWARD LOOKING STATEMENTS**

Statements in this document that are not descriptions of historical facts are forward-looking statements that are based on management's current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition and stock price could be materially negatively affected. In some cases, forward-looking statements can be identified by terminology including "goal," "focus," "aims," "believes," "can," "challenge," "predictable" "will," or the negative of these terms or other comparable terminology. We operate in a rapidly-changing environment and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements the Company may make.

Contact:

Investor Relations  
Mike Cole  
Vice President - MZ North America  
Main: 949-259-4988  
Mobile: 949-444-1341  
[mike.cole@mzgroup.us](mailto:mike.cole@mzgroup.us)  
[www.mzgroup.us](http://www.mzgroup.us)

Source: Nemus Bioscience